


## GSK2983559

Cat. No.:	HY-112038A
Molecular Formula:	C <sub>21</sub> H <sub>28</sub> CaN <sub>4</sub> O <sub>10</sub> PS <sub>2</sub>
Molecular Weight:	611.61
Target:	RIP kinase
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### SOLVENT & SOLUBILITY

In Vitro	DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble)
	DMF : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble)
	Ethanol : < 1 mg/mL (ultrasonic) (insoluble)
	H <sub>2</sub> O : < 0.1 mg/mL (ultrasonic) (insoluble)

### BIOLOGICAL ACTIVITY

Description	GSK2983559 (compound 3) is a potent, specific and oral bioavailable receptor interacting protein 2 (RIP2) kinase inhibitor, which has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples <sup>[1]</sup> .
IC <sub>50</sub> & Target	RIP2 <sup>[1]</sup>

### REFERENCES

[1]. Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA